Madison Square Garden 주식 (NYSE: MSGE)

Madison Square Garden (NYSE:MSGE) 주식

MADISON SQUARE GARDEN ENTERT

Madison Square Garden

Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.

Stock_Whisper_Index_Logo_6-copy

Entertainment

Commodities

Sports

Exclusives

Trading Ideas

BANR

MSGE

MSGS

매주, ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden Entertainment Corp

<a href="https://us02web.zoom.us/j/85838319788?pwd=n2LKwcbMN0tlxXJRPV3NKS5X04FFQa.1#success">https://us02web.zoom.us/j/85838319788?pwd=n2LKwcbMN0tlxXJRPV3NKS5X04FFQa.1#success</a>

Macro Notification

News

Politics

Economics

General

Fed's Bostic Says 'I'm Still There' On Expecting One Cut This Year; Penciled In Three Rate Cuts Next Year

Shares of WeBuy Global Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) are surging Monday morning after the Southeast Asian e-commerce and travel technology company <a href="https://www.benzinga.com/pressreleases/25/06/g46164990/webuy-global-ltd-integrates-coinbase-to-accept-stablecoin-payments-leading-the-way-in-travel-techn">announced</a> it has integrated Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) into its platform, enabling a significant expansion of its payment options.
What To Know: The integration allows customers globally to purchase travel packages and products using hundreds of cryptocurrencies, most notably stablecoins like USDC. This strategic move is designed to eliminate cross-border payment frictions and cater to a growing international clientele in crypto-active markets. 
For its travel brand, WeTrip, which offers tour packages to China, accepting stablecoins could be particularly impactful, as it reduces foreign exchange risks and bypasses costly intermediary banking processes.
&#8220;As we expand globally, offering <a href="https://www.benzinga.com/pressreleases/25/06/g46164990/webuy-global-ltd-integrates-coinbase-to-accept-stablecoin-payments-leading-the-way-in-travel-techn">stablecoin payments</a> allows us to serve the evolving needs of international travelers with greater speed and convenience,&#8221; said Bin Xue, CEO of WeBuy Global.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WBUY shares are trading higher by 30.6% to $7.32 Monday morning. The stock has a significant short interest, with 25.99% of its stock&#8217;s float currently being sold short. WBUY has a 52-week high of $69.27 and a 52-week low of $0.11.
Read Also: <a href="https://www.benzinga.com/pressreleases/25/06/g46092311/webuy-global-ltd-named-one-of-asia-pacifics-fastest-growing-companies-by-financial-times">WeBuy Global Named One of Asia-Pacific&#8217;s Fastest-Growing Companies by Financial Times</a>
<h2 class="wp-block-heading">How To Buy WBUY Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in WeBuy Global&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

COIN

WBUY

WeBuy Global (WBUY) Stock Skyrockets Over 30% After Announcing Coinbase Integration For Crypto Payments

Options

Markets

BBAI

BigBear.ai Hldgs Option Alert: Thu $7.5 Calls Sweep (29) near the Ask: 1161 @ $0.3 vs 907 OI; Earnings 7/31 After Close [est] Ref=$6.845

Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) stock is trading higher on Monday, with a session volume of 11.7 million, compared to the average volume of 70.3K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
The company, which focuses on developing therapeutics that modulate lipid-signaling pathways, including the <a href="https://www.benzinga.com/markets/cannabis/20/08/17057854/the-endocannabinoid-system-8-questions-with-dr-david-knox-1">endocannabinoid system,</a> announced favorable results Monday from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45036783/exclusive-artelo-biosciences-new-peer-reviewed-research-shows-effectiveness-of-psoriasis-candidate-in-animal-models" rel="noreferrer noopener">EXCLUSIVE: Artelo Biosciences&#8217; New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models</a>
The results affirm a promising safety and pharmacokinetic (PK) profile previously <a href="https://www.benzinga.com/pressreleases/25/06/g46165705/artelo-biosciences-announces-positive-first-in-human-data-for-art26-12-a-novel-non-opioid-treatmen" target="_blank" rel="noreferrer noopener">observed in preclinical studies</a>.
The Phase 1 Single Ascending Dose study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The study enrolled 49 subjects.
The key findings include:
<ul class="wp-block-list">
<li>All adverse events (AEs) were mild, transient, and self-resolving. No drug-related AEs were observed in the blinded dataset, and no tolerability issues or safety signals were detected across multiple assessments (vital signs, ECGs, clinical laboratory tests, physical examinations, and visual analog mood scales).</li>
<li>Full dose-exposure profiles were successfully explored. Plasma analysis confirmed dose-dependent, linear absorption across the evaluated range.</li>
<li>A wide safety margin was observed between estimated therapeutic plasma concentrations and the highest exposure levels achieved, supporting potential titration for maximum efficacy in future studies.</li>
</ul>
ART26.12 is the first orally administered, selective, and peripherally restricted FABP5 inhibitor to enter human clinical evaluation.
By targeting FABP5, ART26.12 modulates endogenous lipid signaling molecules that exert analgesic effects through established pathways, including TRPV1, PPAR alpha and cannabinoid receptors, with additional mechanisms such as Nav1.8 under investigation.
The chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 2030, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia.
A Multiple Ascending Dose study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter of this year.
Last week, Artelo Biosciences announced an at-the-market private placement for approximately <a href="https://www.benzinga.com/pressreleases/25/06/g46112865/artelo-biosciences-announces-1-425-million-at-the-market-private-placement-financing" target="_blank" rel="noreferrer noopener">$1.425 million in gross proceeds</a>.
Artelo issued 136,844 shares and 93,179 pre-funded warrants and accompanying warrants to purchase 460,046 shares at $5.82 per share and 230,023 shares at $10.00 per share.
The offering will provide sufficient capital for Artelo to announce clinical data regarding its two Phase 1 study results for ART26.12 and a Phase 2 study readout from the CAReS trial for ART27.13.
Price Action: ARTL stock was up 192.9% at $19.89 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46167555/why-is-hewlett-packard-stock-soaring-on-monday" target="_blank" rel="noreferrer noopener">Why Is Hewlett Packard Stock Soaring On Monday?</a></li>
</ul>
Photo: Shutterstock

Biotech

Cannabis

Health Care

Movers

ARTL

Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?

Howard Lutnick&#8217;s <a href="https://x.com/howardlutnick/status/1937849900546568689">viral social media</a> attack on Jerome Powell reveals the growing tension between Trump&#8217;s economic team and Fed independence—here&#8217;s what investors need to know
Commerce Secretary Howard Lutnick's scathing public attack earlier this week on Federal Reserve Chair Jerome Powell, calling him a &#8220;loser&#8221; and arguing for immediate interest rate cuts to capitalize on tariff revenues. But Lutnick&#8217;s economic reasoning contains several questionable assumptions that could impact your portfolio if implemented.
Don't Miss:
<ul class="wp-block-list">
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
<h2 class="wp-block-heading">The Core Argument: Tariffs as Economic Miracle</h2>
In a lengthy social media post on Wednesday, Lutnick argues that Powell is ignoring massive tariff revenues that could reduce the deficit and justify lower interest rates. His logic follows this sequence:
<ul class="wp-block-list">
<li>Tariffs are generating $30 billion per month in revenue</li>
<li>This revenue reduces the need for government borrowing</li>
<li>Lower borrowing needs should justify lower interest rates</li>
<li>Lower rates would spur economic growth and generate even more tax revenue</li>
</ul>
Lutnick frames this as a &#8220;simple formula&#8221; and suggests Powell is &#8220;afraid to act&#8221; by maintaining current rates.
<h2 class="wp-block-heading">Powell&#8217;s Contrasting View: Inflation Risks Ahead</h2>
Powell has told Congress the Fed can afford to wait and see how Trump&#8217;s tariffs affect the economy before deciding on rate cuts, despite Trump&#8217;s increasingly intense demands for cuts. The Fed chair&#8217;s concerns center on inflation risks rather than revenue opportunities.
Powell has warned that &#8220;tariffs are highly likely to generate at least a temporary rise in inflation,&#8221; with effects that &#8220;could also be more persistent&#8221;. As recently as today, Powell emphasized that the risk of persistent tariff inflation is &#8220;large enough for the central bank to be careful in considering further rate cuts&#8221;.
Trending: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">The Economic Reality Check</h2>
Lutnick&#8217;s analysis contains several problematic assumptions that investors should scrutinize:
Revenue vs. Economic Impact: While tariffs do generate government revenue, they also function as taxes on consumers and businesses. The $30 billion monthly figure Lutnick cites represents money taken out of the private economy—not a pure economic gain.
Inflation Timing: Powell has indicated that bigger-than-expected tariffs will translate into &#8220;higher inflation and slower economic growth,&#8221; with inflation effects that could persist rather than fade quickly. This directly contradicts Lutnick&#8217;s claim that inflationary pressures haven&#8217;t materialized over recent months.
Federal Reserve Independence: The Fed&#8217;s dual mandate focuses on price stability and maximum employment, not optimizing government revenues. Lutnick&#8217;s argument essentially asks the Fed to subordinate monetary policy to fiscal policy—a fundamental shift that could undermine central bank credibility.
<h2 class="wp-block-heading">What This Means for Your Money</h2>
This public spat between Trump&#8217;s Commerce Secretary and the Fed chair signals several potential scenarios for investors:
Scenario 1: Fed Maintains Independence If Powell continues resisting political pressure, expect continued volatility as markets price in the tension between fiscal and monetary policy. Bond markets may reward Fed independence with lower long-term rates, but equity markets could struggle with policy uncertainty.
Scenario 2: Political Pressure Intensifies Escalating attacks on Fed independence could create currency weakness and inflationary expectations, potentially forcing the Fed into a more hawkish stance than desired. This scenario would likely favor commodities and international diversification.
Scenario 3: Compromise Position The Fed might thread the needle with modest rate cuts while emphasizing data-dependent decisions. This middle path could support risk assets while maintaining some monetary policy credibility.
See Also: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
<h2 class="wp-block-heading">The Historical Context Investors Can&#8217;t Ignore</h2>
Previous attempts by presidential administrations to pressure the Fed have generally ended poorly for markets and the economy. The most effective monetary policy typically emerges from independent central banks focused on long-term stability rather than short-term political or fiscal considerations.
Lutnick&#8217;s framing of Powell as obstructionist for maintaining standard Fed protocols suggests a fundamental misunderstanding of central banking&#8217;s role in a complex economy. Investors have historically benefited from Fed independence, even when it creates short-term political friction.
<h2 class="wp-block-heading">Bottom Line for Investors</h2>
While Lutnick&#8217;s tariff revenue calculations may be accurate, his economic logic oversimplifies the complex relationships between trade policy, inflation, and monetary policy. Powell has noted the Fed faces &#8220;a highly uncertain outlook with elevated risks of both higher unemployment and higher inflation&#8221;—precisely the kind of environment where political pressure on monetary policy becomes most dangerous.
Smart investors should prepare for continued volatility as this debate plays out, while remembering that sustainable market gains typically emerge from sound economic fundamentals rather than political pressure campaigns—no matter how loudly they&#8217;re broadcast on social media.
Read Next: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
Image: Shutterstock

Personal Finance

Howard Lutnick's Viral Fed Rant Claims 'Simple Formula' for Rate Cuts—Here's Why Economists Are Cringing

<a href="https://www.bloomberg.com/news/articles/2025-06-30/google-is-betting-on-a-fusion-future-in-power-deal-with-commonwealth" title="https://www.bloomberg.com/news/articles/2025-06-30/google-is-betting-on-a-fusion-future-in-power-deal-with-commonwealth">https://www.bloomberg.com/news/articles/2025-06-30/google-is-betting-on-a-fusion-future-in-power-deal-with-commonwealth</a>

Contracts

GOOG

GOOGL

Reported Earlier: 'Google Is Betting On A Fusion Future In Power Deal With Commonwealth; Google Will Also Invest Again In Commonwealth, Which Expects Its First Commercial Plant Will Generate Power In The Early 2030s' - Bloomberg News

Shares of Gorilla Technology Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) are trading sharply lower Monday morning after the security and business intelligence solutions provider announced a $105 million registered direct offering.
What To Know: The offering is anchored by a $100 million investment from a single new institutional investor, with a large existing shareholder also increasing its position. Gorilla will <a href="https://www.benzinga.com/pressreleases/25/06/46166553/gorilla-announces-105-million-registered-direct-offering-of-common-stock">issue</a> 6 million ordinary shares at a price of $17.50 per share, a notable discount to its previous closing price.
Proceeds from the sale are earmarked for critical business needs, including the establishment of performance guarantees and bid bonds for future projects. Funds will also be allocated to meet requirements for project bids and to finalize previously announced acquisitions, in addition to general working capital.
The <a href="https://www.benzinga.com/pressreleases/25/06/46166553/gorilla-announces-105-million-registered-direct-offering-of-common-stock">offering</a> is anticipated to close around July 2, pending customary closing conditions. Per the company, this capital raise is positioned to strengthen Gorilla&#8217;s financial footing as it pursues new large-scale projects and expands its operations through strategic acquisitions.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GRRR shares are trading lower by 14.6% to $19.12 Monday morning. GRRR has a 52-week high of $44.15 and a 52-week low of $2.09.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46075366/gorilla-technology-grrr-stock-surges-on-agreement-to-acquire-thai-ai-firms">Gorilla Technology Stock Surges On Agreement To Acquire Thai AI Firms</a>
<h2 class="wp-block-heading">How To Buy GRRR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Gorilla Tech&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

GRRR

Gorilla Technology (GRRR) Stock Falls After $105M Offering

<a href="https://www.bloomberg.com/news/articles/2025-06-30/supreme-court-rebuffs-bid-to-protect-coinbase-user-data-from-irs">https://www.bloomberg.com/news/articles/2025-06-30/supreme-court-rebuffs-bid-to-protect-coinbase-user-data-from-irs</a>

'Supreme Court Rebuffs Bid to Protect Coinbase User Data From IRS'- Bloomberg

Fed's Bostic Says Risk Tariff Related Inflation Will Affect Expectations, It's An Open Question; Much Of Tariff Pricing Hasn't Worked Itself Into Economy Yet

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 5 years by 2.17% on an annualized basis producing an average annual return of 16.39%. Currently, Alnylam Pharmaceuticals has a market capitalization of $41.78 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 5 years ago, it would be worth $2,172.18 today based on a price of $322.83 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751292948_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $29 price target.

Price Target

Reiteration

Analyst Ratings

CELC

Needham Reiterates Buy on Celcuity, Maintains $29 Price Target

WIIM

SST stock has given up its prior gain. System1 shares were trading higher. The company announced a $250 million common stock offering.

Macro Economic Events

Fed's Bostic Says Tariff Impacts Will Play Out Over Time

Truist Securities analyst Lucas Servera maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and raises the price target from $125 to $135.

Truist Securities Maintains Buy on XPO, Raises Price Target to $135

Barclays (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCS#NYSE">BCS</a>) and its former CEO Jes Staley will have to defend themselves in a U.S. court over accusations that they misled shareholders about Staley's relationship with the <a href="https://www.benzinga.com/news/topics/25/06/45786407/jeffrey-epsteins-40-million-bet-on-peter-thiels-capital-firm-is-now-worth-170-million-but-his-victims-probably-wont-see-a-dime">late financier Jeffrey Epstein</a>.
A federal judge in Los Angeles ruled that there was sufficient ground for the case to proceed, allowing investors to pursue claims that the bank and its former chief intentionally concealed key information to safeguard Barclays&#8217; reputation and stock value, Reuters reported.
The class-action lawsuit, led by pension funds from New York and St. Louis, focuses on the period between July 22, 2019, shortly after Epstein's arrest, and October 12, 2023. 
Investors argue that Barclays continued to make misleading public statements even after the bank discovered emails suggesting Staley had described Epstein as being &#8220;like family.&#8221;
The complaint points to repeated assurances from Barclays indicating Staley's interactions with Epstein were strictly professional. 
Shareholders also challenge statements suggesting the British Financial Conduct Authority's investigation was limited to whether Staley knew about Epstein's alleged crimes, and not whether he witnessed them.
While U.S. District Judge Maame Ewusi-Mensah Frimpong allowed the core fraud claims against Barclays and Staley to proceed, she limited some parts of the case brought against Barclays Chairman Nigel Higgins.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46166208/bitcoin-etfs-extend-record-2-2b-net-inflows-to-extend-streak-to-11-weeks">Bitcoin ETFs Extend Record $2.2B Net Inflows To Extend Streak To 11 Weeks</a>
Neither Staley's legal team nor lawyers representing Barclays and Higgins provided comments when contacted on Thursday. 
The attorneys representing the shareholders also declined to immediately respond.
Jes Staley, who served as Barclays CEO from 2015 until 2021 and was previously a senior executive at JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), lost his appeal in London on Thursday against a potential ban from the financial sector. 
The UK's Financial Conduct Authority had proposed the ban last year, accusing him of misleading regulators about the nature of his Epstein connections. 
Staley has consistently denied knowing about Epstein's criminal activities and said he had no memory of certain compromising emails.
Epstein, arrested on sex trafficking charges in July 2019, died in his Manhattan jail cell five weeks later.
The case is Merritt v. Barclays Plc et al., filed in the U.S. District Court for the Central District of California under case number 23-09217.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46165366/circle-stock-is-a-must-hold-says-bernstein-heres-why">Circle Stock Is A &#8216;Must Hold,&#8217; Says Bernstein: Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Barclays Faces Epstein Fallout As Former CEO Faces Trial

Truist Securities analyst Lucas Servera maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Buy and raises the price target from $175 to $180.

ODFL

Truist Securities Maintains Buy on Old Dominion Freight Line, Raises Price Target to $180

RBC Capital analyst Michael Carroll maintains Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) with a Sector Perform and lowers the price target from $5 to $4.5.

RBC Capital Maintains Sector Perform on Medical Properties Trust, Lowers Price Target to $4.5

Fed's Bostic Says Advance Warning On Tariffs Have Allowed Firms To Manage Process; There Is Still A Lot Of Uncertainty Where Trade Policy Will Go;  It Will Take Time Before Full Clarity Arrives On Trade Policy

Truist Securities analyst Lucas Pipes maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Hold and raises the price target from $130 to $140.

JBHT

Truist Securities Maintains Hold on JB Hunt Transport Servs, Raises Price Target to $140

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and lowers the price target from $674 to $640.

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $640

Press Releases

WATERLOO SPARKLING WATER NAMED AN OFFICIAL PARTNER OF THE NEW YORK RANGERS AND MADISON SQUARE GARDEN

Madison Square Garden Entertainment Corp. to Host Fiscal 2025 Second Quarter Conference Call

Earnings

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2025 SECOND QUARTER RESULTS

THE MSG FAMILY OF COMPANIES AND PEPSICO EXPAND MULTI-YEAR PARTNERSHIP

THE RADIO CITY ROCKETTES CELEBRATE 100 YEARS OF PRECISION, ATHLETICISM & SISTERHOOD IN 2025

THE MSG FAMILY OF COMPANIES ANNOUNCE INTEGRATED MARKETING PARTNERSHIP WITH LIQUID DEATH

MSG ENTERTAINMENT NAMES DAVID COLLINS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER

SNAPPLE® NAMED OFFICIAL TEA PARTNER OF THE NEW YORK KNICKS, NEW YORK RANGERS AND MADISON SQUARE GARDEN

Real Estate

Madison Square Garden Entertainment Corp. to Host Fiscal 2025 Third Quarter Conference Call

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2025 THIRD QUARTER RESULTS

SPHR

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Liberty Media

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

Starz Entertainment Corp. - Common Shares

Starz Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

Madison Square Garden

뉴스

파트너 / 기고자

벤징가 글로벌